<p>根据公司在最近向证券交易委员会的披露，Kennedy Capital Management LLC 在第二季度将其在 Capricor Therapeutics, Inc.（NASDAQ:CAPR - 免费报告）的持股减少了 51.1%。该基金在季度内出售了 78,468 股后，持有 75,019 股该生物技术公司的股票。Kennedy Capital Management LLC 在最近一个季度末持有的 Capricor Therapeutics 的股份约占 0.16%，价值 74.5 万美元。</p>
<p>获取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
<ul>
<li>Capricor Therapeutics 上涨超过 100%，可能会进一步上涨</li>
</ul>
<p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Rhumbline Advisers 在第二季度将其在 Capricor Therapeutics 的持仓增加了 7.3%。Rhumbline Advisers 现在持有 53,450 股该生物技术公司的股票，价值 53.1 万美元，此前在上个季度购买了 3,636 股。Legal &amp; General Group Plc 在第二季度将其在 Capricor Therapeutics 的股份增加了 8.4%。Legal &amp; General Group Plc 现在持有 41,273 股该生物技术公司的股票，价值 41 万美元，此前在上个季度购买了 3,205 股。Citizens Financial Group Inc. RI 在第二季度将其在 Capricor Therapeutics 的股份增加了 249.2%。Citizens Financial Group Inc. RI 现在持有 35,000 股该生物技术公司的股票，价值 34.8 万美元，此前在上个季度购买了 24,977 股。Geode Capital Management LLC 在第二季度将其在 Capricor Therapeutics 的股份增加了 6.8%。Geode Capital Management LLC 现在持有 963,080 股该生物技术公司的股票，价值 956.5 万美元，此前在上个季度购买了 61,701 股。最后，Simplify Asset Management Inc.在第二季度购买了 Capricor Therapeutics 的新股份，价值约 39.7 万美元。目前，21.68% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级升级与降级</h2>
<p>多家券商最近对 CAPR 发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Capricor Therapeutics 股票的 “卖出（d-）” 评级。Maxim Group 在周四将 Capricor Therapeutics 的目标价从 25.00 美元提高至 50.00 美元，并给予该股票 “买入” 评级。Alliance Global Partners 在 12 月 3 日的研究报告中重申了对 Capricor Therapeutics 股票的 “买入” 评级。Oppenheimer 在周一将 Capricor Therapeutics 的目标价从 22.00 美元提高至 54.00 美元，并给予该股票 “跑赢大盘” 评级。最后，HC Wainwright 在 12 月 3 日的研究报告中将 Capricor Therapeutics 的目标价从 24.00 美元提高至 60.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 34.50 美元。</p>
<p><strong>查看我们关于 CAPR 的最新研究报告</strong></p>
<h2>Capricor Therapeutics 价格表现</h2>
<p>NASDAQ CAPR 在周二开盘价为 28.56 美元。Capricor Therapeutics, Inc.的 1 年最低价为 4.30 美元，1 年最高价为 40.37 美元。该公司的 50 日简单移动平均线为 8.01 美元，200 日简单移动平均线为 8.34 美元。该公司的市值为 13.1 亿美元，市盈率为-15.87，贝塔值为 0.62。</p>
<p>Capricor Therapeutics（NASDAQ:CAPR - 获取免费报告）在 11 月 10 日最后发布了其财报。该生物技术公司报告本季度每股收益（EPS）为（0.54 美元），符合分析师的共识预期（0.54 美元）。平均而言，股票研究分析师预计 Capricor Therapeutics, Inc.在当前财政年度将发布-1.21 的每股收益。</p>
<h2>Capricor Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Capricor Therapeutics, Inc NASDAQ: CAPR 是一家临床阶段的生物技术公司，专注于发现、开发和商业化用于治疗罕见疾病的一流生物治疗药物。Capricor 的主要候选药物 CAP-1002 是一种同种异体细胞疗法，目前正在进行临床开发，以治疗杜氏肌营养不良症。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Capricor Therapeutics</li>
<li>股票平均计算器</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
<li>工业产品股票投资</li>
<li>2026 年最有可能拆分的 3 只股票</li>
<li>3 只提供优厚股息收益的天然气股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Capricor Therapeutics 吗？</h2>
<p>在你考虑 Capricor Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Capricor Therapeutics 并不在名单上。</p>
<p>虽然 Capricor Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Capricor治疗

<p>肯尼迪资本管理公司在第二季度将其在 Capricor Therapeutics 的股份减少了 51.1%。尽管如此，其他机构投资者却增加了他们的持仓。分析师们的评级不一，普遍目标价为 34.50 美元。Capricor 的股票开盘价为 28.56 美元，市值为 13.1 亿美元。该公司专注于针对罕见疾病的生物治疗，CAP-1002 正在进行杜氏肌营养不良症的临床开发</p>

<p>Kennedy Capital Management LLC trimmed its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 51.1% in the second quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 75,019 shares of the biotechnology company's stock after selling 78,468 shares during the quarter. Kennedy Capital Management LLC owned approximately 0.16% of Capricor Therapeutics worth $745,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会的披露，Kennedy Capital Management LLC 在第二季度将其在 Capricor Therapeutics, Inc.（NASDAQ:CAPR - 免费报告）的持股减少了 51.1%。该基金在季度内出售了 78,468 股后，持有 75,019 股该生物技术公司的股票。Kennedy Capital Management LLC 在最近一个季度末持有的 Capricor Therapeutics 的股份约占 0.16%，价值 74.5 万美元。</p>
</div><p>Get <strong>Capricor Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>Capricor Therapeutics 上涨超过 100%，可能会进一步上涨</li>
</ul>
</div><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Rhumbline Advisers increased its position in Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock worth $531,000 after purchasing an additional 3,636 shares in the last quarter. Legal &amp; General Group Plc boosted its stake in shares of Capricor Therapeutics by 8.4% during the 2nd quarter. Legal &amp; General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after purchasing an additional 3,205 shares during the last quarter. Citizens Financial Group Inc. RI boosted its stake in shares of Capricor Therapeutics by 249.2% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company's stock worth $348,000 after purchasing an additional 24,977 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock valued at $9,565,000 after buying an additional 61,701 shares during the last quarter. Finally, Simplify Asset Management Inc. purchased a new position in shares of Capricor Therapeutics during the second quarter valued at approximately $397,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也对该公司的持仓进行了调整。Rhumbline Advisers 在第二季度将其在 Capricor Therapeutics 的持仓增加了 7.3%。Rhumbline Advisers 现在持有 53,450 股该生物技术公司的股票，价值 53.1 万美元，此前在上个季度购买了 3,636 股。Legal &amp; General Group Plc 在第二季度将其在 Capricor Therapeutics 的股份增加了 8.4%。Legal &amp; General Group Plc 现在持有 41,273 股该生物技术公司的股票，价值 41 万美元，此前在上个季度购买了 3,205 股。Citizens Financial Group Inc. RI 在第二季度将其在 Capricor Therapeutics 的股份增加了 249.2%。Citizens Financial Group Inc. RI 现在持有 35,000 股该生物技术公司的股票，价值 34.8 万美元，此前在上个季度购买了 24,977 股。Geode Capital Management LLC 在第二季度将其在 Capricor Therapeutics 的股份增加了 6.8%。Geode Capital Management LLC 现在持有 963,080 股该生物技术公司的股票，价值 956.5 万美元，此前在上个季度购买了 61,701 股。最后，Simplify Asset Management Inc.在第二季度购买了 Capricor Therapeutics 的新股份，价值约 39.7 万美元。目前，21.68% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>A number of brokerages recently issued reports on CAPR. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. Maxim Group raised their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Alliance Global Partners reaffirmed a &#34;buy&#34; rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Oppenheimer increased their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an &#34;outperform&#34; rating in a research report on Monday. Finally, HC Wainwright raised their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $34.50.</p>
<div class="lb-trans"><p>多家券商最近对 CAPR 发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Capricor Therapeutics 股票的 “卖出（d-）” 评级。Maxim Group 在周四将 Capricor Therapeutics 的目标价从 25.00 美元提高至 50.00 美元，并给予该股票 “买入” 评级。Alliance Global Partners 在 12 月 3 日的研究报告中重申了对 Capricor Therapeutics 股票的 “买入” 评级。Oppenheimer 在周一将 Capricor Therapeutics 的目标价从 22.00 美元提高至 54.00 美元，并给予该股票 “跑赢大盘” 评级。最后，HC Wainwright 在 12 月 3 日的研究报告中将 Capricor Therapeutics 的目标价从 24.00 美元提高至 60.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 34.50 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on CAPR</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CAPR 的最新研究报告</strong></p>
</div><h2>Capricor Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Capricor Therapeutics 价格表现</h2>
</div><p>NASDAQ CAPR opened at $28.56 on Tuesday. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37. The business's 50-day simple moving average is $8.01 and its 200-day simple moving average is $8.34. The firm has a market capitalization of $1.31 billion, a P/E ratio of -15.87 and a beta of 0.62.</p>
<div class="lb-trans"><p>NASDAQ CAPR 在周二开盘价为 28.56 美元。Capricor Therapeutics, Inc.的 1 年最低价为 4.30 美元，1 年最高价为 40.37 美元。该公司的 50 日简单移动平均线为 8.01 美元，200 日简单移动平均线为 8.34 美元。该公司的市值为 13.1 亿美元，市盈率为-15.87，贝塔值为 0.62。</p>
</div><p>Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting analysts' consensus estimates of ($0.54). On average, equities research analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Capricor Therapeutics（NASDAQ:CAPR - 获取免费报告）在 11 月 10 日最后发布了其财报。该生物技术公司报告本季度每股收益（EPS）为（0.54 美元），符合分析师的共识预期（0.54 美元）。平均而言，股票研究分析师预计 Capricor Therapeutics, Inc.在当前财政年度将发布-1.21 的每股收益。</p>
</div><h2>Capricor Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Capricor Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.</p>
<div class="lb-trans"><p>Capricor Therapeutics, Inc NASDAQ: CAPR 是一家临床阶段的生物技术公司，专注于发现、开发和商业化用于治疗罕见疾病的一流生物治疗药物。Capricor 的主要候选药物 CAP-1002 是一种同种异体细胞疗法，目前正在进行临床开发，以治疗杜氏肌营养不良症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Capricor Therapeutics</li>
<li>Stock Average Calculator</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>Industrial Products Stocks Investing</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Capricor Therapeutics</li>
<li>股票平均计算器</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
<li>工业产品股票投资</li>
<li>2026 年最有可能拆分的 3 只股票</li>
<li>3 只提供优厚股息收益的天然气股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CAPR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Capricor Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Capricor Therapeutics 吗？</h2>
</div><p>Before you consider Capricor Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Capricor Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Capricor Therapeutics 并不在名单上。</p>
</div><p>While Capricor Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Capricor Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Kennedy Capital Management LLC 减少了其在 Capricor 治疗公司（Capricor Therapeutics, Inc.）$CAPR 的持仓